Shaanxi Xi Yue Pharmaceutical Co., Ltd. (hereinafter referred to as “Xi Yue Pharma”) is a professional manufacturing enterprise mainly engaged in R&D and production of APIs. Xi Yue Pharma was founded in 1968. Its predecessor was the Northwest Second Synthetic Pharmaceutical Factory, which is affiliated to the Ministry of Chemical Industry and is the largest API production base in western China. In 2008, Xi Yue Pharma was acquired by Haichenyunhe Pharmaceutical Technology Co., Ltd. and was transformed into an efficient, high-tech, professional and private high-tech enterprise. The company is headquartered in Xi'an, the ancient capital of China, at the beginning of the Silk Road. It now has two production enterprises, which are located in Huayin Biomedical Industrial Park and Baoji Fufeng Science and Technology Industrial Park, with a total area of more than 200,000 square meters.
Xi Yue Pharma currently has 113 approval numbers, including 23 API approvals and 90 approvals. The products cover cardiovascular and cerebrovascular, nervous system, antipyretic and analgesic, digestive and other fields. The company has established and perfected the quality management system in strict accordance with the new national GMP standards. It has more than 10 production lines of APIs, tablets, capsules and granules. Its production scale, technical level, brand influence and economic benefits rank among the top in the domestic industry. The company's products are mainly sold domestically and are widely used in overseas markets. The domestic market share of Nifedipine and Acetylglutamate is leading, and diclofenac sodium has been sold to countries such as Argentina and Pakistan. The company undertakes international API processing business and has established strategic partnerships with many well-known domestic and foreign companies, such as Pharmaceutical Group, Sinopharm Group and Buchang Pharma.
Xi Yue Pharma has more than 300 employees, including more than 100 professional and technical personnel, and more than 30 senior and intermediate researchers. The company attaches great importance to the development of new products, invests a large amount of funds each year for research and development, and has established a pharmaceutical research institute by a number of doctors and masters. It has long maintained close cooperation with many domestic research institutions in production, research and research to ensure product technology innovation and new product launch, to meet the diverse needs of customers at home and abroad.
Xi Yue Pharma attaches great importance to environmental protection and has passed various inspections of the national environmental assessment of the pharmaceutical industry. The production strictly follows the EHS policy, strengthens the prevention principle of the whole process, and eliminates environmental pollution and social hazard accidents. These ensure a safe, efficient and consistent supply of products. Companies adhering to the "people-oriented, care for health" corporate philosophy, is committed to making Xi Yue Pharma an internationally renowned, domestic leading API pharmaceutical manufacturing enterprise.